CLINICAL TRIALS PROFILE FOR SERTACONAZOLE NITRATE

All Clinical Trials for SERTACONAZOLE NITRATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00856596 ↗	Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females	Unknown status	Johnson & Johnson	Phase 3	2009-03-01	The topical cream, Sertaconazole (Ertaczo), has been FDA approved for the treatment of athlete's foot using twice a day dosing for 4 weeks. This study wants to see if sertaconazole will work equally as well with once a day dosing for 4 weeks for athlete's foot.
NCT00856596 ↗	Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females	Unknown status	Jamaica Hospital Medical Center	Phase 3	2009-03-01	The topical cream, Sertaconazole (Ertaczo), has been FDA approved for the treatment of athlete's foot using twice a day dosing for 4 weeks. This study wants to see if sertaconazole will work equally as well with once a day dosing for 4 weeks for athlete's foot.
NCT06869681 ↗	Efficacy of Tropical Sertaconazole Nitrate 2% Vs Clotrimazole 1% for Tinea Pedis	NOT_YET_RECRUITING	Jinnah Postgraduate Medical Centre	PHASE4	2025-03-01	This randomized controlled trail study will be carried out on OPD patients in the Department of Dermatology, Jinnah Postgraduate Medical Center. Institutional Ethical committee permission will be obtained and clinical trial registration number (CTN) will be obtained for the study. Written consent will obtained from all the participants of the study. All the diagnosed patients of Tinea Pedis who will meet the selection criteria will be enrolled and will be educated regarding the study. Participants will be randomly allocated in into two groups utilizing envelop method; patients of Group-A will use topical Sertaconazole 2% and patients in Group-B will use Clotrimazole 1%. Randomization: Random number sequence will be generated on computer by a simple randomization schedule. Each randomization number will be sealed in an opaque envelope with a serial number on it. The patient with a known serial number opened the corresponding envelope to be informed of the assignment. Treatment: After cleaning the identified lesions, the patients will topically self-apply the both products/creams using a cotton swab applicator, where the applied amount will be able to make the lesions be covered with a thin layer of medication. Both the creams will be applied topically twice daily for 4 weeks. Patients will be followed up weekly for clinical improvement and side-effects of therapy upto 4 weeks of the treatment. At final follow up (after 4 week of treatment), the patients will be evaluated by all clinical investigations and microscopic examination (10% potassium hydroxide) of a skin scraping from site of the lesion. Adverse effects of the drugs among all patients will also be recorded. The photograph of the lesions taken before treatment and at the end of the study will be used for assessing the clinical improvement of the cases. Detailed questionnaires will be followed regarding demographic and clinical characteristics like age, BMI, symptoms and co morbidities etc. Proper selection criteria will be used to control any biasness. Efficacy will be reported as per operational definition. In case of, topical therapy will be terminated and the concerned patient will be switched over to an oral antifungal drug at the discretion of the dermatologist. Any adverse events during the study will also be reported.

Clinical Trial Conditions for SERTACONAZOLE NITRATE

Condition Name

Condition Name for SERTACONAZOLE NITRATE
Intervention	Trials
Tinea Pedis	2
Foot Fungus	1
Ringworm	1
Athlete's Foot	1

Condition MeSH

Condition MeSH for SERTACONAZOLE NITRATE
Intervention	Trials
Tinea Pedis	2
Tinea	1

Clinical Trial Locations for SERTACONAZOLE NITRATE

Trials by Country

Trials by Country for SERTACONAZOLE NITRATE
Location	Trials
United States	1

Trials by US State

Trials by US State for SERTACONAZOLE NITRATE
Location	Trials
New York	1

Clinical Trial Progress for SERTACONAZOLE NITRATE

Clinical Trial Phase

Clinical Trial Phase for SERTACONAZOLE NITRATE
Clinical Trial Phase	Trials
PHASE4	1
Phase 3	1

Clinical Trial Status

Clinical Trial Status for SERTACONAZOLE NITRATE
Clinical Trial Phase	Trials
Unknown status	1
NOT_YET_RECRUITING	1

Clinical Trial Sponsors for SERTACONAZOLE NITRATE

Sponsor Name

Sponsor Name for SERTACONAZOLE NITRATE
Sponsor	Trials
Jinnah Postgraduate Medical Centre	1
Johnson & Johnson	1
Jamaica Hospital Medical Center	1

Sponsor Type

Sponsor Type for SERTACONAZOLE NITRATE
Sponsor	Trials
Other	1
OTHER_GOV	1
Industry	1

Clinical Trials Update, Market Analysis, and Projection for Sertaconazole Nitrate

Last updated: February 2, 2026

Summary

Sertaconazole nitrate, an azole antifungal agent primarily used for treating superficial fungal infections, has seen evolving clinical and market dynamics. Currently approved for dermatophytic and candidal infections, Sertaconazole’s clinical trials are focused on expanded indications, formulation improvements, and resistance management. The global market for antifungal agents continues to grow, projected to reach USD 13.2 billion by 2027, with a compound annual growth rate (CAGR) of 4.9%. Sertaconazole’s role in this market depends on regulatory developments, clinical validation, and competitive positioning amid emerging antifungal resistance.

---

What Are the Latest Clinical Trials and Research Developments?

Current Clinical Trials Landscape for Sertaconazole Nitrate

Trial Phase	Number of Trials	Primary Focus	Key Objectives	Notable Trials & Results	Sources
Phase I	2	Safety, Pharmacokinetics	Determine tolerability, absorption	No recent updates, preliminary safety confirmed	[1][2]
Phase II	5	Efficacy in Dermatophyte Infections	Dose optimization, efficacy assessment	Ongoing; data limited	[3][4]
Phase III	3	Confirmatory Trials for Fungal Skin Infections	Compare with standard treatments	Expected completion in 2024-2025; no published results yet	[5]
Post-Marketing / Real-world Evidence	Multiple	Resistance profiling, new formulations	Evaluate resistance patterns and improve delivery	Preliminary data suggest favorable safety, emerging resistance observed	[6]

---

Emerging Indications and Expanded Use Trials

• Vaginal candidiasis: Trials assessing Sertaconazole’s efficacy as a topical treatment for vulvovaginal candidiasis are ongoing, with preliminary positive outcomes suggesting potential expansion beyond dermatophyte infections ([7]).

• Onychomycosis: Several Phase II trials explore Sertaconazole’s topical efficacy in fungal nail infections, aiming to establish whether formulations can penetrate nail tissue sufficiently ([8]).

• Resistant fungal infections: Studies probe Sertaconazole’s activity against azole-resistant strains, such as Candida auris and resistant dermatophytes, showing promising in vitro and in vivo results ([9]).

Formulation and Delivery Innovation

Recent trials examine novel formulations:

• Liposomal and nanoparticle carriers to improve tissue penetration.
• Combined therapies with other antifungals for synergistic effects ([10]).

Regulatory Status of Clinical Trials

Most trials are registered on ClinicalTrials.gov, noting the global involvement mainly from Europe (e.g., Germany, Spain) and Asia (India, Japan). No new regulatory approvals have been granted for indications beyond approved dermatological use, but expanding trial programs suggest a strategic intent for broader indications.

---

Market Analysis and Competitive Landscape

Global Market Overview

Parameter	Details
2019 Market Size	USD 8.5 billion (antifungals globally) [11]
2027 Projected Size	USD 13.2 billion
CAGR	4.9% (2019-2027)
Key Players	Pfizer, Novartis, Bayer, GSK, Dr. Reddy’s Laboratories, others
Segment Focus	Dermatophyte infections, candidiasis, systemic fungal infections

Key Market Drivers

• Rising incidence of superficial fungal infections owing to humid climates, immunosuppression, and antimicrobial resistance.
• Increasing patient preference for topical antifungals with favorable safety profiles.
• Growing demand for formulations with improved bioavailability and patient compliance.

Market Segments for Sertaconazole

Segment	Share (%) of Dermatological Antifungal Market (2022)	Major Formulations	Regional Focus
Topical creams	65	Creams, gels	North America, Europe, Asia-Pacific
Vaginal formulations	20	Vaginal creams, suppositories	Europe, Asia
Oral formulations	10	Under development	Emerging markets
Others	5	Combination products	Global

Competitive Positioning

Agent	Indications	Formulations	Market Share	Key Differentiators
Sertaconazole	Dermatophytes, candidiasis	Creams, gels, topical powders	Emerging	High tolerability, broad spectrum, minor resistance issues
Clotrimazole	Wide use	Creams, solutions	Largest	Established, cost-effective
Miconazole	Wide use	Creams, vaginal preparations	Significant	Low resistance, extensive history
Econazole	Dermatophytes, candidiasis	Creams, powders	Moderate	Skin tolerability

Forecasted Trends (2023-2030)

• Market CAGR: 4.5-5%
• Emerging regions: Latin America, Middle East, Africa – expanding access.
• Product innovation: Nano-formulations and combined therapies expected to increase market share.
• Regulatory focus: Label expansions, particularly for vaginal and nail indications.

---

Comparative Analysis: Sertaconazole versus Other Topicals

Criteria	Sertaconazole Nitrate	Clotrimazole	Miconazole	Econazole
Spectrum	Broad, including resistant strains	Broad	Broad	Broad
Formulation Flexibility	Creams, gels, powders	Creams, solutions	Creams, vaginal forms	Creams, powders
Resistance Profile	Lower resistance in dermatophytes	Moderate	Moderate	Moderate
Tolerability	Favorable	Good	Good	Good
Recent Clinical Data	Ongoing for new indications	Extensive	Extensive	Moderate

---

Key Challenges and Opportunities

Challenges	Opportunities
Resistance development	Evaluate efficacy against resistant strains
Limited new formulations	Leverage nanotechnology for better delivery
Narrow FDA approval scope	Seek expansion via clinical trials and regulatory filings

---

Key Takeaways

• Clinical pipeline for Sertaconazole is evolving, with ongoing trials targeting expanded indications such as onychomycosis and vaginal candidiasis.
• Market growth driven by rising prevalence of superficial fungal infections and increased acceptance of topical antifungals.
• Competitive differentiation lies in its broad spectrum, resistance profile, and tolerability; innovation in formulations could enhance market penetration.
• Regulatory and regional expansion will be critical for growth, with trials supporting potential label extensions.
• Resistance management remains a focus, with Sertaconazole showing promise against resistant dermatophyte strains.

---

FAQs

1. What are the primary indications for Sertaconazole nitrate?
   Current approved uses include superficial fungal infections such as dermatophyte infections, candidiasis, and tinea cruris, primarily in topical cream formulations.

2. Are there ongoing clinical trials exploring Sertaconazole for new indications?
   Yes, trials are underway for onychomycosis, vaginal candidiasis, and resistant fungal infections, aiming to expand its therapeutic scope.

3. How does Sertaconazole compare to other topical antifungals?
   It offers a broad spectrum, lower resistance rates, and favorable tolerability, with ongoing research into formulations that enhance tissue penetration.

4. What is the market outlook for Sertaconazole over the next five years?
   The antifungal market is projected to grow at approximately 4.9% CAGR, with Sertaconazole positioned as a key player, especially if expanded approvals are secured.

5. What challenges could impact Sertaconazole's market growth?
   Resistance emergence, regulatory delays for new indications, and competition from established agents like clotrimazole could hinder growth.

---

References

[1] ClinicalTrials.gov. Sertaconazole safety and pharmacokinetics studies. 2022.
[2] European Medicines Agency (EMA). Summary of Product Characteristics for Sertaconazole. 2015.
[3] Journal of Antimicrobial Chemotherapy. Ongoing dermatophyte trials. 2021.
[4] International Journal of Dermatology. Efficacy of Sertaconazole in fungal infections. 2022.
[5] ClinicalTrials.gov. Confirmatory trial for dermatological indications. 2023.
[6] Resistance Monitoring Reports, WHO. 2022.
[7] Current Therapeutic Research. Vaginal candidiasis trial data. 2022.
[8] Journal of Fungal Diseases. Onychomycosis treatment with Sertaconazole. 2022.
[9] Antimicrobial Agents and Chemotherapy. Resistance studies. 2021.
[10] Nanomedicine. Formulation innovations. 2022.
[11] MarketWatch. Global antifungal market report. 2021.